1-13 of 13
Jörg Hasford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,

Susanne Saussele, MD, Michael Lauseker, Verena Hoffmann, MA., Ulrike Proetel, MD, Benjamin Hanfstein, MD, Gabriela M. Baerlocher, MD, Dominik Heim, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, PhD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Joerg E. A. Schubert, MD, Hermann Einsele, MD, Matthias Hänel, MD, Anthony D. Ho, MD, PhD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Karsten Spiekermann, MD, Susanne Schnittger, PhD, Markus Pfirrmann, PhD, Andreas Hochhaus, MD, Jörg Hasford, MD, Rüdiger Hehlmann, MD, Martin C Müller, MD, for The SAKK, The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 3762.
https://doi.org/10.1182/blood.V118.21.3762.3762
Published: 2011
Journal Articles

Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV,

Benjamin Hanfstein, MD, Philipp Erben, MD, Susanne Saussele, MD, Michael Lauseker, Ulrike Proetel, MD, Sven Haag, Susanne Schnittger, PhD, Claudia Haferlach, MD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Jörg E. A. Schubert, MD, Hermann Einsele, MD, Mathias Hänel, MD, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD, for The German CML Study Group, for The SAKK
Journal: Blood
Blood (2011) 118 (21): 3773.
https://doi.org/10.1182/blood.V118.21.3773.3773
Published: 2011
Journal Articles

Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV

Susanne Saussele, MD, Michael Lauseker, Ulrike Proetel, MD, Martin C. Müller, MD, Benjamin Hanfstein, MD, Annette Schreiber, MD, Florian Nolte, MD, Gabriela M. Baerlocher, MD, Gerhard Ehninger, MD, Dominik Heim, MD, Dieter K. Hossfeld, MD, PhD, Stefan W. Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Joerg E. A. Schubert, MD, Hermann Einsele, MD, Matthias Hänel, MD, Anthony D. Ho, MD, PhD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Karsten Spiekermann, MD, Wolf Karsten Hofmann, MD, PhD, Jörg Hasford, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, MD, Rüdiger Hehlmann, MD, for The SAKK, for The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 781.
https://doi.org/10.1182/blood.V118.21.781.781
Published: 2011
Journal Articles

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

Benjamin Hanfstein, MD, Martin C. Müller, MD, Philipp Erben, MD, Michael Lauseker, Susanne Saussele, MD, Ulrike Proetel, MD, Susanne Schnittger, PhD, Claudia Haferlach, MD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Jörg E. A. Schubert, MD, Hermann Einsele, MD, Mathias Hänel, MD, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, for The SAKK, for The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 783.
https://doi.org/10.1182/blood.V118.21.783.783
Published: 2011
Journal Articles

Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment

Martin C. Müller, MD, Benjamin Hanfstein, MD, Michael Lauseker, Philipp Erben, MD, Ulrike Proetel, MD, Susanne Schnittger, PhD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Joerg E. A. Schubert, MD, Hermann Einsele, MD, Matthias Hänel, MD, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Susanne Saussele, MD, Andreas Hochhaus, MD, for The SAKK, for The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 1681.
https://doi.org/10.1182/blood.V118.21.1681.1681
Published: 2011
Journal Articles

Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV

Martin C. Müller, MD, Andreas Hochhaus, MD, Michael Lauseker, Susanne Jung-Munkwitz, MD, Markus Pfirrmann, PhD, Armin Leitner, MD, Stefan W. Krause, MD, Nadine Pletsch, MD, Benjamin Hanfstein, MD, Susanne Schnittger, PhD, Alois Gratwohl, MD, Jörg Hasford, MD, Susanne Saussele, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 669.
https://doi.org/10.1182/blood.V116.21.669.669
Published: 2010
Journal Articles

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients

Philipp Erben, MD, Benjamin Hanfstein, MD, Umang Munjal, PhD, Hannah Daikeler, MD, Mridul Agrawal, Jr., Juliana Popa, MD, Daniel Nowak, MD, Armin Leitner, MD, Dieter K Hossfeld, MD, Hans J Kolb, MD, Stefan W Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M Baerlocher, MD, Jörg Hasford, MD, Hermann Heimpel, MD, Susanne Saussele, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, Martin C Mueller, MD
Journal: Blood
Blood (2010) 116 (21): 671.
https://doi.org/10.1182/blood.V116.21.671.671
Published: 2010
Journal Articles

Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV.

Susanne Saussele, MD, Nadine Pletsch, MD, Michael Lauseker, Armin Leitner, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Martin C. Müller, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Stefan W. Krause, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Anthony D. Ho, MD, FRCPC, Christiane Falge, MD, Matthias Hänel, MD, M. Pfreundschuh, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, MD, Karsten Spiekermann, MD, Steffen Koschmieder, MD, Cornelius F. Waller, MD, Martin Bentz, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, Jörg Hasford, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 3411.
https://doi.org/10.1182/blood.V116.21.3411.3411
Published: 2010
Journal Articles

Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML

Armin Leitner, MD, Susanne Saussele, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gudrun Göhring, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Michael Lauseker, Markus Pfirrmann, PhD, Jörg Hasford, MD, Andreas Hochhaus, Rüdiger Hehlmann, MD, The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 355.
https://doi.org/10.1182/blood.V116.21.355.355
Published: 2010
Journal Articles

Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV

Rüdiger Hehlmann, MD, Susanne Jung-Munkwitz, MD, Michael Lauseker, Martin C. Müller, MD, Armin Leitner, MD, Nadine Pletsch, MD, Ulrike Proetel, MD, Alois Gratwohl, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Christiane Falge, MD, Anthony D. Ho, MD, FRCPC, Matthias Hänel, MD, Michael Pfreundschuh, MD, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, CA, MD, Karsten Spiekermann, MD, Steffen Koschmieder, Cornelius F. Waller, MD, Martin Bentz, MD, Stefan W. Krause, MD, Benjamin Hanfstein, MD, Susanne Schnittger, PhD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Andreas Hochhaus, Susanne Saussele, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 357.
https://doi.org/10.1182/blood.V116.21.357.357
Published: 2010
Journal Articles

Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia.

Rudiger Hehlmann, MD, Markus Pfirrmann, MSc, Andreas Hochhaus, MD, Martin C. Müller, MD, Jörg Hasford, MD, Hans-Jochem Kolb, MD, Hermann Heimpel, MD, Dieter K. Hossfeld, MD, Alois Gratwohl, MD, the German CML-Study Group
Journal: Blood
Blood (2006) 108 (11): 427.
https://doi.org/10.1182/blood.V108.11.427.427
Published: 2006
Journal Articles

Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.

Dorle Messerer, PhD, Jutta Engel, MD, Jörg Hasford, PhD, Markus Schaich, MD, Silke Soucek, Gerhard Ehninger, MD, Christina Sauerland, PhD, Thomas Büchner, MD, Dietger W. Niederwieser, MD, Rainer Krahl, MD, Jürgen Krauter, MD, Irina Schäfer, Arnold Ganser, MD, Claire Schleich, Hartmut Döhner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2005) 106 (11): 747.
https://doi.org/10.1182/blood.V106.11.747.747
Published: 2005
Journal Articles

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Rüdiger Hehlmann, Andreas Hochhaus, Hans-Jochem Kolb, Jörg Hasford, Alois Gratwohl, Hermann Heimpel, Wolfgang Siegert, Jürgen Finke, Gerhard Ehninger, Ernst Holler, Ute Berger, Markus Pfirrmann, Alexander Muth, Axel Zander, Axel A. Fauser, Axel Heyll, Christoph Nerl, Dieter K. Hossfeld, Helmut Löffler, Hans Pralle, Wolfgang Queißer, and Andreas Tobler
Journal: Blood
Blood (1999) 94 (11): 3668–3677.
https://doi.org/10.1182/blood.V94.11.3668
Published: 1999